And AMAG stills trades under $26? Unreal! Come longs it's time to blow the #$%$ shorts out of the water. Should be trading above $30 tomorrow, $40 by next earnings report.
Answer from Frank Thomas Pres and Chief Operating Officer
So, I really don’t see a scenario where it doesn’t get approved. There is always -- this is the FDA, so it’s supposed there is always potential for delay, but I feel pretty good about where we are. We answered all of the FDA’s questions very completely, confirmed that the data they received was the data they were looking for. So, I feel I think as good as one can feel. But, so, I just don’t envision the scenario where it’s not approved.
In terms of the timing and launch, I think those are swing factors and our guidance tries to capture a range of potential scenarios that are going in assumption right now is that the product will be approved next month, or before and that we’ll be launching in Q2. Our sales force, our newly expanded sales force of over 100 reps is selling what they have today. And so, our sales reps today are focused on encouraging new physicians who are currently not prescribing Makena or who potentially utilizing compounded product, to move to Makena. We are working with insurers to encourage them to discourage the use of compounded product where Makena is appropriate. And so, our sales reps are continuing today to sell the products that they have and grow the products, not the product that we have in hand which is the multi-dose vial. And so, we will continue to sell that until we have approval and launch the single-dose preservative-free.
But, as you point out, we are really encouraged by the response we got in market research that physicians who to today are either not using hydroxyprogesterone caproate on their at risk patients or physicians who are comfortable using the single-dose preservative-free compounded version will switch to the Makena single-dose preservative-free when launched. So, we are pretty excited about the upside opportunities that product is launched and the growth opportunities that we see.
The company has taken corrective action and states that the situation does not impact its previously reported financial results.
Ackman's lost more than $666 million on paper on his Valeant position since Monday's close. His losses to date on his Valeant investment are estimated at north of $2 billion.
The problems continue to mount for embattled Valeant Pharmaceuticals Shares are down 10% after hours on robust volume on the news that it is expected to restate earnings after an internal review. The likely reason is the accounting of drug sales to Philidor.
S&P Capital reduce their price target from $90 to $30.
Sure hope you took my advice & sold this pos for a small profit. Other wise welcome to the bagholder club! Enjoy! See you at $15......
VRX downgraded to "sector underperform", target reduced to $24
Un-real & u idiots are buying into this BS? So now we have to wait for bankruptcy in May in stead of April. Oh well I can wait another month for this pos to go to ZERO!
The rules have two main parts, each of which could affect the Pfizer deal. First, the government would go after what it calls "serial inverters," large companies created through multiple inversions or takeovers of U.S. companies. The government would disregard U.S. assets acquired by such companies over the previous three years.
Consider Allergan. The company's current heft is the result of several cross-border deals, starting with the 2013 inversion of Actavis Inc., a small New Jersey-based drugmaker, through a takeover of Ireland-based Warner Chilcott PLC. What followed was a string of ever-larger deals, culminating in Actavis's $66 billion takeover of U.S.-based Allergan Inc. last year.
Under the new Treasury regulations, those deals would be disregarded for the purposes of determining Allergan's size under the tax law. The three-year window would cover the 2015 merger of Actavis and Allergan, Actavis' $25 billion purchase of Forest Laboratories Inc. in 2014, and the original $5 billion Warner Chilcott deal.
Stripping those deals out of Allergan's closing market capitalization of $106 billion could make it too small to serve as Pfizer's inversion partner under federal rules that disfavor lopsided mergers, or limit the financial benefits of the arrangement.
To reap the full benefits of inverting, the U.S. company's shareholders should own between 50% and 60% of the merged entity, which requires a partner of carefully calibrated size. Above that, some restrictions apply, including rules making it harder for companies to access foreign profits. The Pfizer-Allergan deal is structured so that Pfizer's shareholders will own 56% of the company.
Mr. Willens said the new percentage in the Pfizer-Allergan deal would be at least 60% and could approach 80%, above which all benefits of the inversion are lost.
"It certainly puts a crimp in the deal and it's not out of the question I suppose that Pfizer would want to rethink the transaction given the dev
That's a 14% increase! 34.5% of the float. All time high short interest, while the stock price is at a 2 year low. Not good! Look for AMAG to slide back down to $15 or less. If long, cut your loses & move on. Amag is a dog!
Deutsche analyst Nandan Amladi also cut his PT to $35 (from $50), saying that the slowdown in Verint's emerging market business and slower-than-expected enterprise growth will weigh on results going forward.
Credit Suisse analyst Michael Nemeroff, meanwhile, slashes his PT to $29 (from $45), arguing that Verint lacks near-term catalysts to drive the stock higher.
Treasury Secretary Jacob Lew said in a new statement. "This will have an important effect, but we cannot stop these transactions without new legislation. I urge Congress to move forward with anti-inversion legislation this year," Lew added.
IRS has no power to create new laws, congress must enact & pass new law. This is nothing more then political gesturing.
With in the last 30 days,earing estimates have drop from $5.57 to $507. Pumper Jefferies drop his high estimate of $6.34 to $5.44, but maintain his $70 pt. Really? Drop you earning estimates by a $1 & still maintain $70 pt. The guy has no credibility. That's a huge drop, but then again he was way out of line with his estimates. So nine analyst have a range of $4.34 to $5.07 for 2016, making Amag a extremely under vale stock. Amag should be training at $40 to $50 not this insane $23 price.